NHD Global
Growth Hormone & IGF · GHRF analogue research
Scientific Product Dossier
Tesamorelin is a peptide modeled on a natural signal that prompts the pituitary gland to release growth hormone. Researchers study its downstream effects on IGF-1 and body-fat distribution. Trials of a pharmaceutical preparation in adults with HIV and lipodystrophy focused on deep abdominal fat, which is different from total body weight. NHD catalog material is for research, not the approved finished medicine. The sections below explain these distinctions and the information to check before requesting a quote.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
Randomized controlled research reported significant reductions in visceral adipose tissue and improvements in selected body-composition measures in the defined HIV-lipodystrophy population.
Population- and indication-specific evidence; it cannot support general weight-loss, bodybuilding or anti-aging claims.
Read the primary studyFDA labeling authorizes a specific tesamorelin drug product for reducing excess abdominal fat in adults with HIV and lipodystrophy and states it is not indicated for weight-loss management.
Approval does not apply to third-party catalog research material.
Read the primary studyFDA labeling warns that the regulated product increases IGF-1 and may cause glucose intolerance or diabetes.
The approved indication is not general weight management, and the label does not establish safety or identity for research catalog material.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 2 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 20 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Controlled clinical research in a defined adult HIV-lipodystrophy population; not general obesity research.
View primary recordAuthoritative source for the narrow indication and the explicit statement that the approved product is not for weight-loss management.
View primary recordThird-party publications selected for direct relevance.
Falutz J, et al. Journal of Acquired Immune Deficiency Syndromes. PMID 20101189 · DOI 10.1097/QAI.0b013e3181cbdaff
U.S. Food and Drug Administration. 2025 labeling record for BLA 022505.
Concise answers for researchers comparing identity, evidence and catalog variants.
The main human evidence comes from randomized controlled research in adults with HIV and lipodystrophy. A pharmaceutical tesamorelin product reduced visceral abdominal fat and improved belly-image distress. IGF-1 rose as expected. Limb fat and under-skin abdominal fat were unchanged, and glucose measures were not disturbed in that trial. These results belong to that specific population and product. They do not extend to general weight loss, athletic performance, or anti-aging, and say nothing about catalog material.
An FDA-approved branded tesamorelin medicine exists, but its authorization is narrow: reducing excess abdominal fat in adults with HIV and lipodystrophy, with explicit labeling that it is not for weight-loss management. That covers one specific drug product studied in a defined patient group. Catalog tesamorelin is a different research chemical. Its identity, purity, and behavior must be established per lot. Approval, clinical evidence, and research-vial status are three separate things.
Tesamorelin is a growth hormone-releasing factor analogue that stimulates pituitary growth hormone secretion and downstream IGF-1.
No. The FDA-approved branded medicine has a narrow indication for reducing excess abdominal fat in adults with HIV and lipodystrophy and is not indicated for weight-loss management.
No. This is research, development and manufacturing material and must not be represented as the regulated branded drug.
Tell us which records your project requires. Availability and scope must be confirmed for the selected material. Published papers are not batch certificates, and this page does not confirm that a lot-specific COA is available.
Request the storage conditions for the exact supplied form and selected variant. A temperature stated for another supplier or a clinical drug preparation is not a verified storage specification for NHD catalog material.
No. Visceral fat is fat around organs inside the abdomen. Body weight includes fat, muscle, bone, water and other tissues. A change in visceral-fat measurements cannot be substituted for the same change in total body weight.
Send the exact product name, selected catalog variant, required quantity, destination and documents needed for the project. Specify whether the amount refers to powder mass or measured peptide content. Availability, price, lead time and document scope require confirmation.
No. A paper describes the material and methods used in that study. It does not establish the identity, purity or content of a different supplied lot. Ask which records actually apply to the requested material; do not assume a COA is available.
Knowledge center
Owned educational content connected to this family.
An evidence-led review of tesamorelin trials in adults with HIV-associated abdominal fat accumulation, including endpoints, limits and FDA-labeled context.
Updated October 1, 2026
A clear comparison between a tesamorelin research material and the FDA-approved EGRIFTA WR finished drug, focusing on formulation, documentation and evidence transfer.
Updated October 1, 2026
A CT scan can tell researchers about the amount of abdominal fat and a separate property called attenuation. Those measurements are different. This guide…
Updated October 9, 2026
A small trial looked at the relationship between tesamorelin and cognition and brain connectivity. The main measures found no clear improvement, but machine learning…
Updated October 12, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: TSM2 · 2 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
